What are the precautions for using Ripotinib?

Repotrectinib (Repotrectinib) is a targeted drug used to treat non-small cell lung cancer. In its clinical studies, a variety of adverse reactions and cautions were observed, and physicians need to closely monitor patients' health when using this drug. The following are the main precautions for repotinib:

1. Central nervous system (CNS) adverse reactions: Clinical studies have shown that some patients will experience symptoms including dizziness, ataxia (such as unsteady gait and balance disorder), and cognitive impairment (such as memory and concentration impairment). The incidence of these adverse reactions was similar in patients with and without CNS metastases. Therefore, patients are advised to avoid driving or operating machinery when experiencing related symptoms to ensure the safety of themselves and others.

2. Interstitial lung disease/Pneumonia: Ripotinib may cause interstitial lung disease (ILD) or pneumonia. In this case, the drug may need to be permanently discontinued. Physicians should monitor patients regularly for new or worsening lung symptoms. If a patient is suspected of having ILD/pneumonitis, repotinib should be discontinued immediately and permanent discontinuation should be considered if confirmed.

3. Hepatotoxicity: The use of repotinib may cause liver function damage, including increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as hyperbilirubinemia. Therefore, liver function should be checked every two weeks during the first month of treatment and then monthly as clinically necessary.

4. Myalgia and increased creatine phosphokinase: Ripotinib may cause muscle pain with or without an increase in creatine phosphokinase (CPK). Patients should report any unexplained muscle pain or weakness and have CPK levels monitored regularly during treatment, especially within the first month of starting treatment.

5. Hyperuricemia: The use of repotinib may cause hyperuricemia. In the study, it was found that a patient without a history of gout needed to use urate-lowering drugs. Serum uric acid levels need to be monitored regularly before and during treatment, and urate-lowering drugs should be used as needed.

6. Skeletal fractures: Clinical studies of Ripotinib show that the incidence of fractures is 2.3%, involving multiple parts, including ribs, spine, and hips. Physicians should promptly evaluate patients who develop signs or symptoms of a fracture, but there are currently no data on the drug's effect on the healing of known fractures and the risk of future fractures.

7. Embryo-Fetal Toxicity: Pregnant women taking Ripotinib may cause fetal damage. Animal studies show that use of this drug during pregnancy can cause fetal malformations. Therefore, females of reproductive potential are advised to use effective non-hormonal contraception during use of repotinib and for two months after the last dose. At the same time, male patients of childbearing potential should also take effective contraceptive measures during treatment and within four months after the last treatment.

In short, during the treatment of repotinib, doctors need to carefully monitor the patient's health status and deal with adverse reactions in a timely manner to ensure the patient's safety and therapeutic effect.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html